

References

R-94

1. Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival and safety of (177Lu-DOTA0,Tyr3) octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. *Clin Cancer Res.* 2017;23(16):4617-4624.
2. FDA News Release: January 26, 2018: FDA approves new treatment for certain digestive tract cancers.
3. National Comprehensive Cancer Network (NCCN) Guidelines Version 31.20178 – March 29, 2018. June 13, 2017. Neuroendocrine and Adrenal Tumors.
4. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotate for midgut neuroendocrine tumors. *N Engl J Med.* 2017;376:125-135.
5. U.S. National Library of Medicine Clinical Trials.gov: Identifier NCT01578239: a study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumours (NETTER-1).
6. van Vliet EI, Krenning EP, Teunissen JJ, et al. Comparison of response evaluation in patients with gastropancreatic and thoracic neuroendocrine tumors after treatment with (177Lu-DOTA0,Tyr3) octreotate. *J Nucl Med.* 2013;54(10):1689-1696.
7. Highlighted and Full Prescribing Information revised 1/2018.